Product Catalog
Generic Norvasc (Amlodipine, Norvasc® equivalent)
Amlodipine is in a class of medications called calcium channel blockers. Amlodipine widens the blood vessels, making it easier for the heart to pump and reducing its workload. Amlodipine is used to treat hypertension (high blood pressure) and to treat angina (chest pain). Amlodipine may also be used for purposes other than those listed in this medication guide.
This product will arrive to you in 14-24 business days (free shipping worldwide)
10mg
| Quantity | Price | Price per pill | Returning customer price | Bonus | |
|---|---|---|---|---|---|
| 10 | $ 47.00 | $ 4.70 | $ 42.00 | ---- | Add to cart |
| 20 | $ 50.00 | $ 2.50 | $ 45.00 | ---- | Add to cart |
| 30 | $ 53.00 | $ 1.77 | $ 47.00 | ---- | Add to cart |
Drug Medical Information
OBESITY AS DISEASE: LIMITATIONS OF THE BODY MASS INDEX
As the name suggests, the BMI measures body mass, not body fat. It is possible for an individual to have a high BMI but a relatively low body fat mass. Typically, this can occur in athletes and very muscular, well-exercised individuals who have developed a high lean muscle mass and a low body fat mass. Even individuals undergoing weight management, particularly those who embrace intense and frequent exercise as part of their programme, may find that although they are losing fat their weight remains the same -because they lose body fat but gain muscle mass their BMI will appear relatively unchanged. The former New Zealand international rugby player Jonah Lomu is a case in point. At his peak, his height was 196 cm, his weight 118 kg, and therefore his BMI was 31, and within the range for obesity. He does, however, have an extremely well-developed muscle mass and his body fat mass is reputed to be only 9%. He is not therefore at any increased risk of comorbid disease. The BMI on this occasion is a misleading measurement.
The WHO range for BMI was developed for the study of white, Caucasian populations. It has become apparent in recent years that some racial groups do not demonstrate the same comorbid disease risk at a given BMI. Chinese and Asian peoples seem to be genetically predisposed to higher comorbid disease with much less body fat. It would seem appropriate to use an alternative model when assessing these patients, and perhaps the threshold for intervention should be changed to a lower BMI level.
*5/312/5*
